Companies link to combine TMR (transmyocardial revascularisation) and gene therapy:
This article was originally published in Clinica
Cardiac laser developer Cardiodyne and biopharmaceutical company Endovasc are to co-develop new treatments for angina, heart failure and other conditions which combine transmyocardial revascularisation (TMR) and liposomal therapeutics. Irvine, California-based Cardiodyne, which is developing a system which combines TMR with ECG-synchronised gene injection, will have certain rights to products developed through the collaboration.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.